The DOI matches its Crossref record.
Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus.
Open accessAbstract
Three benzenoid ansamycin antibiotics (herbimycin, macbecin, and geldanamycin) were found to reduce the intracellular phosphorylation of p60src at a permissive temperature (33 degrees C) in a rat kidney cell line infected with a temperature-sensitive mutant of Rous sarcoma virus. This effect was accompanied by morphological changes from the transformed to the normal phenotype. The filamentous staining pattern of actin fibers was observed in the cells treated with these antibiotics at 33 degrees C. Removal of the antibiotics allowed the cells to revert to the transformed morphology. Ansamitocin, another benzenoid ansamycin, and naphthalenoid ansamycins such as streptovaricin and rifamycins did not show this effect. Pulse-labeling of the antibiotic-treated cultures with 32Pi showed a marked reduction of 32P radioactivity incorporated into p60src. A parallel experiment with [35S]methionine showed that synthesis of p60src was slightly inhibited. The immune complex prepared by mixing the herbimycin-treated cell extracts with antibody against p60src was inactive in vitro in phosphorylating the complex itself. On the contrary, the immune complex derived from untreated cells was active in vitro even in the presence of the antibiotics. These results suggest that benzoquinonoid ansamycins have no direct effect on src kinase but destroy its intracellular environment, resulting in an irreversible alteration of p60src and loss of catalytic activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Integrin function: molecular hierarchies of cytoskeletal and signaling molecules.
Miyamoto, S., Teramoto, H., Coso, O. A., Gutkind, J. S., Burbelo, P. D., Akiyama, S. K., & Yamada, K. M. (1995) · The Journal of cell biology · doi:10.1083/jcb.131.3.791 · Cited by 1,203
Role of the Heat Shock Response and Molecular Chaperones in Oncogenesis and Cell Death
Jolly, C. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.19.1564 · Cited by 1,048
Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities
Hu, C., Yang, J., Qi, Z., Wu, H., Wang, B., Zou, F., Mei, H., Liu, J., Wang, W., & Liu, Q. (2022) · MedComm · doi:10.1002/mco2.161 · Cited by 779
Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells.
Emoto, Y., Manome, Y., Meinhardt, G., Kisaki, H., Kharbanda, S., Robertson, M., Ghayur, T., Wong, W. W., Kamen, R., & Weichselbaum, R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00305.x · Cited by 670
HSP90 as a new therapeutic target for cancer therapy: the story unfolds
Maloney, A., & Workman, P. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.1.3 · Cited by 531
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent
Supko, J. G., Hickman, R. L., Grever, M. R., & Malspeis, L. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00689048 · Cited by 510
Schulte, T. W., & Neckers, L. M. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050817 · Cited by 478
Ridley, A. J., & Hall, A. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06550.x · Cited by 467
Langholz, O., Röckel, D., Mauch, C., Kozlowska, E., Bank, I., Krieg, T., & Eckes, B. (1995) · The Journal of cell biology · doi:10.1083/jcb.131.6.1903 · Cited by 397
Targeting multiple signal transduction pathways through inhibition of Hsp90
Zhang, H., & Burrows, F. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0549-9 · Cited by 377
Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer
Goetz, M. P., Toft, D., Reid, J., Ames, M., Stensgard, B., Safgren, S., Adjei, A. A., Sloan, J., Atherton, P., Vasile, V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.119 · Cited by 336
Pratt, W. B. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.297 · Cited by 335
The Hsp90 chaperone complex as a novel target for cancer therapy
Goetz, M. P., Toft, D. O., Ames, M. M., & Erlichman, C. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg316 · Cited by 334
Update on Hsp90 Inhibitors in Clinical Trial
Kim, Y., Alarcon, S., Lee, S., Lee, M.-J., Giaccone, G., Neckers, L., & Trepel, J. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789895728 · Cited by 311
Bacterial lipopolysaccharide stimulates protein tyrosine phosphorylation in macrophages.
Weinstein, S. L., Gold, M. R., & DeFranco, A. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.10.4148 · Cited by 311
Mancini, M., Anderson, B. O., Caldwell, E., Sedghinasab, M., Paty, P. B., & Hockenbery, D. M. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.138.2.449 · Cited by 305
Geldanamycin as a Potential Anti-Cancer Agent: Its Molecular Target and Biochemical Activity
Neckers, L., Schulte, T. W., & Mimnaugh, E. (1999) · Investigational New Drugs · doi:10.1023/a:1006382320697 · Cited by 301
Chaperones in cell cycle regulation and mitogenic signal transduction: a review
Helmbrecht, K., Zeise, E., & Rensing, L. (2000) · Cell Proliferation · doi:10.1046/j.1365-2184.2000.00189.x · Cited by 278
NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones
Siegel, D., Yan, C., & Ross, D. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.017 · Cited by 272
Under cover: causes, effects and implications of Hsp90‐mediated genetic capacitance
Sangster, T. A., Lindquist, S., & Queitsch, C. (2004) · BioEssays · doi:10.1002/bies.20020 · Cited by 251
Metadata
- Authors
- Uehara, Y., Hori, M., Takeuchi, T., & Umezawa, H.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 1986-06
- Volume
- 6
- Issue
- 6
- Pages
- 2198-2206
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2100092765
- Cited by
- 233
- References
- 0
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.